The use of interferon-gamma therapy in chronic granulomatous disease

Recent Patents on Anti-Infective Drug Discovery

Volumn 3, Issue 3, 2008, Pages 225-230

  Errante, Paolo R ^a   Frazão, Josias B ^a   Condino Neto, Antonio ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Chronic granulomatous disease; Cytochrome b558; gp91 phox; Granulocyte; Human primary immunodeficiency; Interferon gamma; Macrophage; NADPH oxidase; Phagocyte oxidase

Indexed keywords

ANTIBIOTIC AGENT; GAMMA INTERFERON; KYNURENINE; NITRIC OXIDE; PARACETAMOL; RECOMBINANT GAMMA INTERFERON; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 2;

AUTOSOMAL RECESSIVE INHERITANCE; BACTERIAL INFECTION; BACTERICIDAL ACTIVITY; CHRONIC GRANULOMATOUS DISEASE; CLINICAL TRIAL; DRUG EFFICACY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG SAFETY; FLU LIKE SYNDROME; GASTROINTESTINAL DISEASE; GENE MUTATION; HUMAN; INFECTION SENSITIVITY; LUNG DISEASE; MOLECULAR GENETICS; MYALGIA; MYCOSIS; NONHUMAN; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; REVIEW; RNA SPLICING; TRANSCRIPTION REGULATION;

EID: 58149109206     PISSN: 1574891X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489108786242378     Document Type: Review

References (92)

1. Wiseman H, Halliwell B. Damage to DNA by reactive oxygen and nitrogen species: Role in inflammatory disease and progression to cancer. Biochem J 1996; 313:17-29.
2. Burg ND, Pillinger MH. The neutrophil: Function and regulation in innate and humoral immunity. Clin Immunol 2001; 99:7-17.
3. + flux. Nature 2002; 416: 291-277.
4. Segal AW, Jones OT. Neutrophil cytochrome B in chronic granulomatous disease. Lancet I 1979; 1036-1037.
5. Parkos CA, Allen RA, Cochrane CG, Jesaitis AJ. Purified cytochrome B from human granulocyte plasma membrane is comprised of two polypeptides with relative molecular weights of 91,000 and 22,000. J Clin Invest 1987; 80:732-742.
6. Lomax KJ, Leto TL, Nunoi H, Gallin JI, Malech HL. Recombinant 47-kilodalton cytosol factor restores NADPH oxidase in chronic granulomatous disease. Science 1989; 245: 409-412.
7. Leto TL, Lomax KJ, Volpp BD, et al. Cloning of a 67-kD neutrophil oxidase factor with similarity to a noncatalytic region of p60c-src. Science 1990; 248:727-730.
8. El Benna J, Faust LP, Babior BM. The phosphorylation of the respiratory burst oxidase component p47phoxduring neutrophil activation. Phosphorylation of sites recognized by protein kinase C and by proline-directed kinases. J Biol Chem 1994; 269: 23431-23436.
9. Quinn MT, Parkos CA, Walker L, Orkin SH, Dinauer MC, Jesaitis AJ. Association of a Ras-related protein with cytochrome B of human neutrophils. Nature 1989; 342: 198-200.
10. Gabig TG, Crean CD, Mantel PL, Rosli R. Function of wild-type or mutant Rac2 and Rap1a GTPases in differentiated HL60 cell NADPH oxidase activation. Blood 1995; 85: 804-811.
11. Knaus UG, Morris S, Dong HJ, Chernoff J, Bokoch GM. Regulation of human leukocyte p21-activated kinases through G protein-coupled receptors. Science 1995; 269: 221-223.
12. Assari T. Chronic granulomatous disease; fundamental stages in our understanding of CGD. Med Immunol 2006; 5: 1-8.
13. Johnston RB, Baehner RL. Chronic granulomatous disease: correlation between pathogenesis and clinical findigs. Pediatrics 1971; 48: 730-739.
14. Regelman W, Hays N, Quie PG. Chronic granulomatous disease: historical perspective and clinical experience at the University of Minnesota Hospital. In. Advances in host defenses mechanisms. Eds. J.I. Galin & A.S. Fauci. New York, Raven Press, 1983; 3-23.
15. Tauber AI, Borregard N, Simons E, Wright J. Chronic granulomatous disease: A syndrome of phagocyte oxidase deficiencies. Medicine 1983; 62: 286-309.
16. Forrest CB, Forehand JR, Axtel RA, Roberts RL, Johnston RB. Clinical features and management of chronic granulomatous disease. Hematol Oncol Clin North Am 1988; 2: 253-266.
17. Mouy R, Fischer A, Vilmer E, Seger R, Griscelli C. Incidence, severity and prevention of infections in chronic granulomatous disease. J Pediatr 1989; 114: 555-560.
18. Bellinati-Pires R, Melki SE, Colletto GMDD, Carneiro-Sampaio MMS. Evaluation of a fluorochrome assay for assessing the bacterial activity of neutrophils in human phagocyte dysfunctions. J Immunol Methods 1989; 119: 189-196.
19. Lazarus GM, Neu HC. Agents responsible for infection in chronic granulomatous disease of childhood. J Pediatr 1975; 86: 415-417.
20. Cohen MS, Isturiz RE, Malech HL, Root RK. Fungal infection in chronic granulomatous disease. Am J Med 1981; 71: 59-66.
21. Seger R. Inborn errors of oxygen-dependent microbial killing by neutrophils. In: Herausgegeben VP, Frick GA eds. Advances in Internal Medicine and Pediatrics. Berlin, Springer-Verlag 1984; 46-52.
22. Wolfson JJ, Quie PG, Laxdal S, Good RA. Roentgenologic manifestations in children with a genetic defect of polymorphonuclear leukocyte function: Chronic granulomatous disease of childhood. Radiology 1968; 91: 37-48.
23. Cohen MS, Leong PA, Simpson DM. Phagocytic cells in periodontal defense. J Periodontol 1985; 56: 611-617.
24. Ament ME, Ochs HD. Gastrointestinal manifestations of chronic granulomatous disease. N Engl J Med 1973; 288: 382-387.
25. Chin TW, Stiehm ER, Falloon J, Gallim J. Corticosteroids in the treatment of obstructive lesions of chronic granulomatous disease. J Pediatr 1987; 111: 349-352.
26. Payne NR, Hays NT, Regelman WE, Sorenson M, Mills EL, Quie PG. Growth in patients with chronic granulomatous disease. J Pediatr 1983; 102: 397-399.
27. Dinauer MC, Orkin SH, Brown R, Jesaitis AJ, Parkos CA. The glycoprotein encoded by the X-linked chronic granulomatous disease locus is a component of the neutrophil cytochrome b complex. Nature 1987; 327: 717-720.
28. Holmes B, Page AR, Good RA. Studies of the metabolic activity of leukocytes from patients with a genetic abnormality of phagocytic function. J Clin Invest 1967; 46: 1422-1432.
29. Cassatella MA, Bazzoni F, Flynn RM, Dusi S, Trinchieri G, Rossi F. Molecular basis of interferon-gamma and lipopolysaccharide enhancement of phagocyte respiratory burst capability. Studies on the gene expression of several NADPH oxidase components. J Biol Chem 1990; 265: 20241-20246.
30. Gupta JW, Kubin M, Hartman L, Cassatella M, Trinchieri G. Induction of expression of genes encoding components of the respiratory burst oxidase during differentiation of human myeloid cell lines induced by tumor necrosis factor and gamma-interferon. Cancer Res 1992; 52: 2530-2537.
31. Skalnik DG. Transcriptional mechanisms regulating myeloidspecific genes. Gene 2002; 284: 1-21.
32. Heyworth PG, Curnutte JT, Rae J, et al. Hematologically important mutations: X-linked chronic granulomatous disease (second update). Blood Cells Mol Dis 2001; 27: 16-26.
33. Ezekowitz RAB. Chronic granulomatous disease: an update and a paradigm for the use of interferon-gamma as adjuvant immunotherapy in infectious diseases. Curr Top Microbiol Immunol 1992; 181: 283-292.
34. Curnutte JT. Conventional versus interferon-gamma theraphy in chronic granulomatous disease. J Infect Dis 1993; 167 Suppl 1: S8-12.
35. International Chronic Granulomatous Disease Cooperative Study Group. A controlled trial of interferon gamma to prevent infection in chronic granulomatous disease. N Engl J Med 1991; 324: 509-516.
36. Woodman RC, Erickson RW, Rae J, Jaffe HS, Curnutte JT. Prolonged recombinant interferon-γ therapy in chronic granulomatous disease: Evidence against enhanced neutrophil oxidase activity. Blood 1992; 79: 1558-1562.
37. Rex JH, Bennet JE, Gallin JI, Malech HL, DeCarlo ES, Melnick DA. in vivo Interferon-gamma therapy augments the in vitro ability of chronic granulomatous disease neutrophils to damage Aspergillus hyphae. J Infect Dis 1991; 163: 849.
38. Murray HW. Interferon-gamma and host antimicrobial defense: Current and future applications. Am J Med 1994; 97: 459-467.
39. Johnson RB. Clinical aspects of chronic granulomatous disease. Curr Opin Hematol 2001; 8: 17-22.
40. Marciano BE, Wesley R, DeCarlo ES, et al. Long-term interferon-γ therapy for patients with chronic granulomatous disease. CID 2004; 39: 692-699.
41. Ezekowitz RAB, Orkin SH, Newburger PE. Recombinant interferon gamma augments phagocyte superoxide production and X-chronic granulomatous disease gene expression in X-linked variant chronic granulomatous disease. J Clin. Invest 1987; 80: 1009-1016.
42. Bolinger AM, Taeubel MA. Recombinant interferon gamma for treatment of chronic granulomatous disease and other disorders. Clin Pharm 1992; 11: 834-850.
43. Vitale MK, Willwerth-Fortin J, Robbins K. Management of children on interferon therapy. Pediatr Nurs 1993; 19: 230-234.
44. Malmvall BE, Follin P. Successful interferon-gamma therapy in a chronic granulomatous disease (CGD) patient suffering from Staphylococcus aureus hepatic abcess and invasive Candida albicans infection. Scand J Infect Dis 1993; 25: 61-66.
45. Steinmmann CG, Rosemkaimer F, Leitz G. Clinical experiences with interferon-alpha and interferon-gamma. Int Rev Exp Pathol 1993; 34: 193-207.
46. Hague RA, Easthman EJ, Lee REJ, Cant AJ. Resolution of hepatic abscess after interferon gamma in chronic granulomatous disease. Arch Dis Child 1993; 69: 443-445.
47. Conte D, Fraquelli M, Capsoni F, Giacca M, Zentilin L, Bardella MT. Effectiveness of IFN-γ for liver abscesses in chronic granulomatous disease. J Interferon Cytokine Res 1999; 19: 705-710.
48. Condino-Neto A, Muscara MN, Bellinati-Pires R, et al. Effect of theraphy with recombinat human interferon-gamma on the release of nitric oxide by neutrophils and mononuclear cells from patents with chronic granulomatous disease. J Interferon Cytokine Res 1996; 16: 357-364.
49. Ahlin A, Larfars G, Elinder G, Palmblad J, Gyllenhammar H. Gamma interferon treatment of patients with chronic granulomatous disease is associated with augment production of nitric oxide by polymorfhonuclear neutrophils. Clin Diagn Lab Immunol 1999; 6: 420-424.
50. Sechler JMG, Malech HL, White CJ, Gallin JI. Recombinant human interferon-γ reconstitutes defective phagocyte function in patients with chronic granulomatous disease of childhood. Proc Natl Acad Sci USA 1988; 85: 4874-4878.
51. Ezekowitz RA, Dinauer MC, Jaffe HS, Orkin SH, Newburger PE. Partial correction of the phagocyte defect in patients with X-linked chronic granulomatous disease by subcutaneous interferon gamma. N Engl J Med 1988; 319: 146-151.
52. Bemiller LS, Roberts DH, Starko KM, Curnutte JT. Safety and effectiveness of long-term interferon gamma therapy in patients with chronic granulomatous disease. Blood Cells Molecule Diseases 1995; 21: 239-247.
53. Boehm U, Klamp T, Groot M, Howard JC. Cellular responses to interferon-gamma. Annu Rev Immunol 1997;15: 749-795.
54. Goldberg M, Belkowski LS, Bloom B. Regulation of macrophage function by interferon-γ. J Clin Invest 81990; 5: 563-569.
55. Schiff DE, Rae J, Martin TR, Davis BH, Curnutte JT. Increased phagocyte FcγRI expression and improved Fcγ-receptor-mediated phagocytosis after in vivo recombinant human interferon-γ treatment of normal human subjects. Blood 1997; 90: 3187-3194.
56. Kemmerich B, Small GJ, Pennington JE. Relation of cytosolic calcium to the microbiocidal activation of blood monocytes by recombinant gamma interferon. J Infect Dis 1986; 154: 770-777.
57. Iyengar R, Stuehr DJ, Marletta MA. Macrophage synthesis of nitrite, nitrate and N-nitrosamines: Precursors and role of the respiratory burst. Proc Natl Acad Sci USA 1987; 84: 6369-6373.
58. Jendrossek V, Peters AMJ, Buth S, et al. Improvement of superoxide production in monocytes from patients with chronic granulomatous disease by recombinat cytokines. Blood 1993; 81: 2131-2136.
59. Weening RS, Leitz GJ, Seger RA. Recombinant human interferon-gamma in patients with chronic granulomatous disease-European follow uo study. Eur J Pediatr 1995; 154: 295-298.
60. Ahuja SS, Brown MR, Fleisher TA, Ahuja S, Malech HL. Autocrine activation of hematopoietic progenitor-derived myelomonocytic cells by IFN-γ gene transfer. J Immunol 1996; 156: 4345-4353.
61. Nevanlinna, H., Fagerholm, R., Tommiska, J.: WO08062105 (2008).
62. Skalnik DG, Strauss EC, Orkin SH. CCAAT displacement protein as a repressor of the myelomonocytic-specific gp91-phox gene promoter. J Biol Chem 1991; 266: 16736-6744.
63. Luo W, Skalnik DG. CCAAT displacement protein competes with multiple transcriptional activators for binding to four sites in the proximal gp91phox promoter. J Biol Chem 1996; 271: 18203-8210.
64. Shaughnessy, J.D., Barlogie, B., Zhan, F.: US20087371736 (2008).
65. Eklund AE, Luo W, Skalnik DG. Characterization of Three promoter elements and cognate DNA binding protein(s) necessary for IFN-γ Induction of gp97-phox Transcription. J Immunol 1996;157: 2418-2429.
66. Newburger PE, Skalnik DG, Hopkins PJ, Eklund EA, Curnutte JT. Mutations in the promoter region of the gene for gp91-phox in Xlinked chronic granulomatous disease with decreased expression of cytochrome b558. J Clin Invest 1994; 94: 1205-1211.
67. Woodman RC, Newburger PE, Anklesaria P, et al. A new X-linked variant of chronic granulomatous disease characterized by the existence of a normal clone of respiratory burst-competent phagocytic cells. Blood 1995; 85: 231-241.
68. Islam MR, Fan C, Fujii Y, et al. PU.1 is dominant and HAF-1 supplementary for activation of the gp91(phox) promoter in human monocytic PLB-985 cells. J Biochem 2002; 131: 533-540.
69. Eklund EA, Jalava A, Kakar R. Tyrosine phosphorylation of HOXA10 decreases DNA binding and transcriptional repression during interferon γ-induced differentiation of myeloid leukemia cell lines. J Biol Chem 2000; 275(26): 20117-20126.
70. Hornbeck, P., Goss, V., Lee, K., Gu, T.L., Moritz, A.: WO08009004 (2008).
71. phox mouse knout-out model of chronic granulomatous disease. J Exp Med 1995; 182: 751-758.
72. Jackson SH, Miller GF, Segal BH, et al. IFN-γ is effective in reducing infections in the mouse model of chronic granulomatous disease (CGD). J Interferon Cytokine Res 2001; 21: 567-573.
73. Romani L, Fallarino F, De Luca A, et al. Defective tryptophan catabolism underlies inflammation in mouse chronic granulomatous disease. Nature Letters 2008: 451: 211-216.
74. + channel is essential for innate immunity. Nature 2004; 427: 853-858.
75. Condino-Neto A, Whitney C, Newburger P. Dexamethasone but not indomethacin inhibits human phagocyte nicotinamide adenine dinucleotide phosphate oxidase activity by down-regulating expression of genes encoding oxidase components. J Immunol 1998; 161: 4960-4967.
76. phox expression. J Biol Chem 1998; 273: 13957-13965.
77. phox Expression. J Immunol 1999; 163: 6095-6105.
78. Mead JR, Hughes TR, Irvine SA, Singh NN, Ramji DP. Interferon-γ stimulates the expression of the inducible cAMP early repressor in macrophages throug the activation of casein kinase 2. J Biol Chem 2003; 278: 17741-17751.
79. phox gene. J Biol Chem 2002; 277: 9103-9111.
80. -245 heavy-chain gene expression and nicotinamide-adenine dinucleotide phosphate hydrogenase oxidase in human leukemic myeloid cells. J Clin Invest 1989; 83: 1570-1579.
81. Newburger PE, Ezekowitz RAB, Whitney C, Wright J, Orkin SH. Induction of phagocyte cytochrome B heavy chain gene expression by interferon-γ Proc Natl Acad Sci USA 1988; 85: 5215-5219.
82. Evans SW, Rennick D, Farrar WL. Identification of a signal-transduction pathway shared by hematopoietic growth factors with diverse biological specificity. Biochem J 1987; 244: 683-691.
83. Hamilton TA, Becton DL, Somers SD, Gray PW, Adams DO. Interferon-gamma modulates protein kinase C activity in murine peritoneal macrophages. J Biol Chem 1985; 260: 1378-1381.
84. Fan XD, Goldberg M, Bloom BR. Interferon-γ-induced transcriptional activation is mediated by protein kinase C. Proc Natl Acad Sci USA 1988; 85: 5122-5125.
85. Heyworth PG, Shrimpton CF, Segal AW. Localization of the 47 kDa phospoprotein involved in the respiratory-burst NADPH-oxidase of phagocytic cells. Biochem J 1989; 260: 243-248.
86. Rotrosen D, Nunoi H, Gallin JI, Malech HL. Evidence for interaction of neutrophil 47 kD phosphoprotein with cytochrome b558 during activation of the respiratory burst. Clin Res 1989; 37: 438-441.
87. Clark RA, Malech HL, Gallin JI, et al. Genetic variants of chronic granulomatous disease: Prevalence of deficiencies of two cytosolic components of the NADPH oxidase system. N Engl J Med 1989; 321: 647-652.
88. Weening RS, Klein A, Boer M, Ross D. Effect of interferon-γ, in vitro and in vivo, on mRNA levels of phagocyte oxidase components. J Leuc Biol 1996; 60: 716-720.
89. Muhleback TJ, Gabay J, Nathan CF, et al. Treatment of patients with chronic granulomatous disease with recombinant human interferon-gamma does not improve oxidative metabolism, cytochrome b558 content or levels of four antimicrobial proteins. Clin Exp Immunol 1992; 88: 203-206.
90. Condino-Neto A, Newburger PE. Interferon-gamma improves splicing efficiency of CYBB gene transcriptis in an interferon-responsive variant of chronic granulomatous disease due to a splicing site consensus region mutation. Blood 2000; 95: 3548-3554.
91. Ishibashi F, Mizukami T, Kanegasaki S, et al. Improved superoxide-generating ability by interferon due to splicing pattern change of transcripts in neutrophils from patients with a splice site mutation in CYBB gene. Blood 2001; 98: 436-441.
92. Nunoi H, Ishibashi F, Mizukami T, Hidaka F. Clinical evaluation of interferon-gamma treatment to chronic granulomatous disease patients with splice mutations. Jpn J Infect Dis 2004; 57: 25-26.